Collectively, these data support the idea that targeting AngII/AT1R signaling with RASi can effectively reduce tumor desmoplasia and thereby decrease solid stress, increase tumor perfusion, reduce hypoxia, enhance T cell infiltration and antitumor immunity, and improve delivery and efficacy of anticancer drugs. The gene discussed is AGTR1; the disease is neoplasm.